Avinger has announced it has received FDA clearance for a smaller, longer version of its Ocelot interventional chronic total occlusion crossing catheter, according to a news release.
Clearance of the Ocelot | PIXL comes a month after Avinger received FDA clearance for the Ocelot catheter, which the company describes as the "first-ever" CTO crossing device with onboard imaging.
The Ocelot catheter is designed to allow physicians to see from inside an artery during a procedure using optical coherence tomography. The Ocelot | PIXL provides physicians with a choice between 135cm or 150cm working length to navigate lesions.
"With its smaller profile and longer length, Ocelot | PIXL is designed to bring all the benefits of Ocelot to help physicians treat more patients with smaller arteries," said John B. Simpson, PhD, MD, Avinger founder and CEO, in the release. "Because Ocelot | PIXL, like the original Ocelot catheter, uses real-time intravascular imaging via optical coherence tomography, I'm confident more legs will be saved, and more patients will walk home happy."
Avinger is headquartered in Redwood City, Calif.
Related Articles on FDA Clearances:
Andrew Technologies Receives FDA Clearance for Lipoplasty System
Quidel Receives FDA Clearance for Handheld Molecular Diagnostic Test for C. Difficile
Lutronic Receives FDA Clearance for Phototherapy System